Ephrin Receptor

Cat. No.

A39912

CAS No.

131086-98-1

Urolithin D

Synonyms: 3,4,8,9-Tetrahydroxy urolithin

Urolithin D is a selective antagonist of the EphA receptor, specifically inhibiting EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. This compound exhibits significant antioxidant activity by scavenging free radicals and repairing oxidized DNA damage. Furthermore, Urolithin D promotes fatty acid oxidation and suppresses triglyceride accumulation through activation of the AMPK signaling pathway. It is a valuable reagent for research in tumor biology, metabolic disorders, and inflammatory conditions.

Cat. No.

A84691

CAS No.

1639159-47-9

UniPR129

UniPR129 is a potent, orally active antagonist of Eph/ephrin interactions. It effectively inhibits the EphA2-ephrin-A1 interaction with an IC50 of 945 nM and a Ki of 370 nM. This compound has demonstrated the ability to inhibit angiogenesis and exhibits both antitumor and neuroprotective properties. UniPR129 is suitable for research applications in cancer and neurological disorders, including colorectal cancer and optic neuropathy.

Cat. No.

A84694

CAS No.

3031514-44-7

Targefrin

Targefrin is a potent EphA2-targeting agent that functions as an antagonist. It exhibits high affinity for the EphA2 ligand-binding domain, with a dissociation constant of 21 nM and an IC50 value of 10.8 nM. Targefrin induces internalization and degradation of the EphA2 receptor in various pancreatic cancer cell lines, making it a valuable tool for research on cancer biology and therapeutic targeting of EphA2-related pathways.

Cat. No.

A84696

CAS No.

1809170-68-0

UniPR1447

UniPR1447 is a dual antagonist of EphA2 and EphB2, exhibiting an IC50 of 6.6 μM for the inhibition of the EphA2-ephrin-A1 interaction. This compound serves as a valuable tool in research focused on the role of Eph receptors in cellular processes such as angiogenesis, tumor progression, and neural development. Its application in studies targeting EphA2 and EphB2 signaling pathways contributes to understanding their implications in various diseases, making UniPR1447 a relevant reagent for therapeutic exploration.

Cat. No.

A84698

CAS No.

2938227-14-4

UniPR505

UniPR505 is an EphA2 antagonist with an IC50 value of 0.95 µM. This compound exhibits significant anti-angiogenic properties, making it a valuable tool for research related to vascular biology and cancer therapy. Its ability to inhibit the EphA2 receptor pathway allows for potential applications in studying tumor growth and angiogenesis.

Cat. No.

A84703

CAS No.

313701-92-7

EPHA4 antagonist-1

EPHA4 antagonist-1 is a selective antagonist of the EphA4 receptor, known for its role in cell signaling, particularly in neuronal development and angiogenesis. This compound effectively inhibits ephrin-A5 binding to the EphA4 Fc receptor with an IC50 value of 10 μM, demonstrating its potency in disrupting EphA4-mediated signaling pathways. The compound's dual action as an EphA2 receptor antagonist expands its utility in biological research, making it valuable for studies on Eph receptor interactions and their implications in cancer and neurobiology.

Cat. No.

A84705

CAS No.

2085767-98-0

UniPR500

UniPR500 is a competitive antagonist of the EphA2 receptor, exhibiting a Ki value of 0.78 μM. This compound effectively inhibits the binding of biotinylated ephrin-A1 to EphA2 in a dose-dependent manner, with an IC50 of 1.1 μM. UniPR500 is valuable for research applications focusing on cellular signaling pathways and the role of EphA2 in various diseases.